Peptide Association
Start Your Consultation
All peptides
OncologyFDA Approved

Bortezomib (Velcade)

Subcutaneous injection, Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortezomib disrupts the ubiquitin-proteasome pathway, stabilizing pro-apoptotic factors and inhibiting NF-kB activation, which is constitutively active in many hematologic malignancies.

Mechanism of Action

It was the first proteasome inhibitor approved for cancer treatment and fundamentally changed the treatment landscape of multiple myeloma.

Research Summary & Key Findings

FDA-approved for multiple myeloma and mantle cell lymphoma. VISTA trial established bortezomib-melphalan-prednisone (VMP) as a standard of care for transplant-ineligible myeloma patients. APEX trial demonstrated superior response rates and time to progression vs. dexamethasone in relapsed myeloma (Richardson et al., NEJM, 2005). Peripheral neuropathy is dose-limiting, mitigated by subcutaneous rather than IV administration.

Clinical Status

FDA Approved

Bortezomib (Velcade) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injectionIntravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Degarelix (Firmagon)

FDA Approved

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of ...

View details

Start Your Consultation

Get an AI-proposed Bortezomib (Velcade) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Bortezomib (Velcade).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.